Stealth BioTherapeutics has resubmitted a new drug application for its Barth syndrome treatment following an FDA rejection. The company faces regulatory hurdles in generating sufficient data for this ultra-rare disease drug affecting about 150 U.S. patients. Stealth has publicly shared its FDA rejection letter to rally support amid funding and review timeline concerns. The drug is currently available under expanded access, with patient advocates emphasizing its life-saving potential.